News Verily plans digital ophthalmology joint venture with Santen Verily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen.
News Oxford Biomedica signs ophthalmology R&D deal with Santen UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
Partner Content Partner Content Queen's University Belfast and Santen to Present Opening Key... Ophthalmic Drugs Conference London
Events Partner Content Ophthalmic Drugs - Europe's Leading Ophthalmic Conference Ophthalmic Drugs Conference
Partner Content Partner Content Boehringer Ingelheim, Novaliq, Santen, Shire, at Europe's Le... SMi’s Leading Ophthalmic Conference
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
